CN1017245B - 咪唑啉酮化合物的制备方法 - Google Patents

咪唑啉酮化合物的制备方法

Info

Publication number
CN1017245B
CN1017245B CN87107864A CN87107864A CN1017245B CN 1017245 B CN1017245 B CN 1017245B CN 87107864 A CN87107864 A CN 87107864A CN 87107864 A CN87107864 A CN 87107864A CN 1017245 B CN1017245 B CN 1017245B
Authority
CN
China
Prior art keywords
compound
pyridyl
chemical formula
following chemical
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CN87107864A
Other languages
English (en)
Chinese (zh)
Other versions
CN87107864A (zh
Inventor
武田幹男
稻毛勝
和田博
玉木元
落合乔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CN87107864A publication Critical patent/CN87107864A/zh
Publication of CN1017245B publication Critical patent/CN1017245B/zh
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN87107864A 1986-11-14 1987-11-13 咪唑啉酮化合物的制备方法 Expired CN1017245B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27265586 1986-11-14
JP272655/86 1986-11-14

Publications (2)

Publication Number Publication Date
CN87107864A CN87107864A (zh) 1988-08-31
CN1017245B true CN1017245B (zh) 1992-07-01

Family

ID=17516947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN87107864A Expired CN1017245B (zh) 1986-11-14 1987-11-13 咪唑啉酮化合物的制备方法

Country Status (16)

Country Link
US (1) US4886817A (enExample)
EP (1) EP0268229B1 (enExample)
JP (1) JPS63239281A (enExample)
KR (1) KR930002488B1 (enExample)
CN (1) CN1017245B (enExample)
AT (1) ATE78033T1 (enExample)
AU (1) AU597444B2 (enExample)
CA (1) CA1304376C (enExample)
DE (1) DE3780259T2 (enExample)
DK (1) DK597687A (enExample)
ES (1) ES2046193T3 (enExample)
FI (1) FI90869C (enExample)
GR (1) GR3005227T3 (enExample)
HU (1) HU198199B (enExample)
IE (1) IE61446B1 (enExample)
IL (1) IL84409A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636439A (zh) * 2013-10-07 2016-06-01 先正达参股股份有限公司 除草化合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600430A (en) * 1985-02-22 1986-07-15 Eli Lilly And Company Pyridinylimidazolidinone compounds
GB9224144D0 (en) * 1992-11-18 1993-01-06 Erba Carlo Spa Phenyl-imidazolidinone derivatives and process for their preparation
JP3916092B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
US7129359B2 (en) 2002-07-09 2006-10-31 National Health Research Institutes Imidazolidinone compounds
CN1822836A (zh) * 2003-07-11 2006-08-23 埃尔比昂股份公司 用对苯并二氮杂䓬受体的α3亚基具有选择性的化合物治疗或预防中枢神经系统病症的方法
WO2005082054A2 (en) * 2004-02-26 2005-09-09 Sosei Co., Ltd. Combinations for the treatment of fungal infections
US7259174B2 (en) * 2004-05-25 2007-08-21 National Health Research Institutes Imidazolidinone compounds
WO2006078698A1 (en) * 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
EP1987009A1 (en) 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
PE20110341A1 (es) 2006-08-15 2011-06-21 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
AU2013206248B2 (en) * 2008-06-27 2016-06-23 Xenon Pharmaceuticals Inc. Organic compounds
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
CN102840229B (zh) * 2012-08-31 2015-11-18 中国舰船研究设计中心 可调心螺旋桨轴承装置
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
BR112017023894A2 (pt) 2015-06-03 2018-07-17 F. Hoffmann-La Roche Ag derivados de etinila

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ184081A (en) * 1976-06-01 1980-10-08 Velsicol Chemical Corp 1-thiazol-2-yl-1 3-imidazolidn-2-ones
US4604127A (en) * 1984-07-17 1986-08-05 Eli Lilly And Company Herbicidal pyridazinylimidazolidinone compounds
AU568789B2 (en) * 1985-02-22 1988-01-07 Mitsui Toatsu Chemicals Inc. 3,3'-dinitrodiphenylether from m-dinitrobenzene
US4600430A (en) * 1985-02-22 1986-07-15 Eli Lilly And Company Pyridinylimidazolidinone compounds
JPH06133172A (ja) * 1992-10-20 1994-05-13 Fujitsu General Ltd ファクシミリ装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636439A (zh) * 2013-10-07 2016-06-01 先正达参股股份有限公司 除草化合物

Also Published As

Publication number Publication date
FI874865L (fi) 1988-05-15
DE3780259D1 (de) 1992-08-13
JPH05396B2 (enExample) 1993-01-05
IL84409A (en) 1991-12-15
GR3005227T3 (enExample) 1993-05-24
IL84409A0 (en) 1988-04-29
DE3780259T2 (de) 1992-12-24
DK597687D0 (da) 1987-11-13
EP0268229B1 (en) 1992-07-08
HUT45983A (en) 1988-09-28
KR880006231A (ko) 1988-07-22
FI90869B (fi) 1993-12-31
US4886817A (en) 1989-12-12
CA1304376C (en) 1992-06-30
KR930002488B1 (ko) 1993-04-02
EP0268229A3 (en) 1990-09-19
JPS63239281A (ja) 1988-10-05
AU597444B2 (en) 1990-05-31
ATE78033T1 (de) 1992-07-15
IE61446B1 (en) 1994-11-02
AU8112587A (en) 1988-05-19
IE873063L (en) 1988-05-14
ES2046193T3 (es) 1994-02-01
CN87107864A (zh) 1988-08-31
HU198199B (en) 1989-08-28
EP0268229A2 (en) 1988-05-25
FI90869C (fi) 1994-04-11
DK597687A (da) 1988-05-15
FI874865A0 (fi) 1987-11-04

Similar Documents

Publication Publication Date Title
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1118464C (zh) 新颖嘧啶衍生物及其制法
CN1017245B (zh) 咪唑啉酮化合物的制备方法
CN1378544A (zh) 取代的唑系化合物
CN1374953A (zh) 含氮的6－员芳香环化合物
CN1221417A (zh) 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
CN1213307A (zh) 新的取代的咪唑化合物
CN87107875A (zh) 四氢化萘衍生物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1109054A (zh) 噁唑烷-2-酮衍生物
CN1160402A (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1138581A (zh) 取代的联苯磺酰胺类内皮素拮挤剂
CN1094726A (zh) 噻唑烷二酮衍生物，它们的制备方法和用途
CN1227547A (zh) 芳基链烷酰基哒嗪
CN1067889A (zh) 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法
CN1206407A (zh) 取代的乙烯基吡啶衍生物和含有它们的药物
CN1070488C (zh) 杀灭螺旋杆菌用的取代芳烷基硫代烷基硫代吡啶
CN1768055A (zh) 作为代谢型谷氨酸受体－5调制剂的四环咪唑衍生物
CN1323306A (zh) 萘啶衍生物
CN87108111A (zh) 一种新颖的咪唑衍生物及其制备方法
CN1585762A (zh) 作为nmda受体配体的吡啶衍生物
CN1030753A (zh) 制备新的取代n-(3-羟基-4-哌啶基)苯甲酰胺的方法
CN1293061C (zh) 新的3－氨基－1－苯基－1h－[1,2,4]三唑的支链取代氨基衍生物、其制备方法和含有它们的药物组合物
CN87107226A (zh) 内酰胺衍生物及其制备
CN1107843A (zh) 二氢化茚衍生物和其制法及合成该衍生物的中间体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C13 Decision
GR02 Examined patent application
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee